Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

The huge premium drug maker Alexion Pharmaceuticals is paying for Synageva BioPharma—$8.4 billion, or more than double Synageva’s market value—shows how hot the market has become for rare ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

Is Alexion over-valued? I think its limited growth potential means the stock is dead money.

Alexion Pharmaceuticals Inc. has reached a tentative settlement with U.S. authorities under which the company would pay less than $25 million to resolve claims it violated an antibribery law. The ...

Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4-billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no ...

A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.

Alexion, AstraZeneca Rare Disease, and DHL Express have teamed up to initiate Ireland's “first” complete transition to sustainable aviation fuel (SAF) for the international air delivery of ...